15353-j-veluchamy

152 | Chapter 6 Table 1: List of biotech NK cellular therapies and NK cell function enhancing compounds Company NK cell product Product characteristics Fortress Biotech Inc. CNDO-109 Tumor primed NK cells Multimmune GmbH ENKASTIM-ev a synthetic peptide which mimics Hsp70 and activates NK cells ex vivo Glycostem Therapeutics oNKord ® NK cells derived from umbilical cord blood (UCB) progenitor cells NantKwest Inc. Activated NK-92 cells (aNK cell) IL-2 dependent tumor cell derived NK cell line High affinity NK cells (haNK) aNK cells genetically modified to express CD16 for ADCC with therapeutic mAbs Target - activated NK cells (taNK) aNK cells genetically modified to express CARs Green Cross Lab Cell MG4101 Ex vivo expanded NK cells derived from CD3 depleted unrelated donors Gamida Cell NAM-NK cells Nicotinamide based PBNK cell culture system Celgene Cellular Therapeutics NK cells NK cells derived from UCB and placenta. Fate Therapeutics Inc. iNK cells NK cells derived from induced pluripotent stem cells Sorrento Therapeutics Inc CARs to enhance tumor homing of NK-92 cells NK-92 cells CAR targeting programming death ligand-1 and NK-92 CAR targeting receptor tyrosine kinase like orphan receptor to increase NK-92 tumor homing. Nkarta Therapeutics NKG2D CARs NKG2D CARs developed with NK-92 and PBNK to enhance the functions of NKG2D receptor in NK cells Ziopharm Oncology Inc. HLA gene editing Zinc finger nuclease technology to delete HLA-A sequences from allogeneic NK cells, allowing them to evade recipient T cell killing. Kyowa Hakko Kirin Mogamulizumab Fc optimized anti CCR4 CD20 mAb Genentech Obinutuzumab Fc optimized anti CD20 mAb Mentrik Biotech, LLC Ocaratuzumab Fc optimized anti CD20 mAb Roche Glycart Imgatuzumab Fc optimized anti EGFR mAb Affimed N.V. AFM13 Bispecific antibody binding to CD16a on NK cells and CD30 on tumor cells AFM22 Bispecific antibody binding to CD16a on NK cells and epidermal growth factor receptor (EGFR) vIII on tumor cells AFM24 Bispecific antibody binding to CD16a on NK cells and wild type EGFR on tumor cells